Ftse Mib
34.099,67
-0,80%
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
NASDAQ
19.621,68
1,77%
Bitcoin
98.050,00
1,19%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cytokinetics Inc (CYTK) Cytokinetics Inc (CYTK) Notizie

CYTK

Cytokinetics (CYTK)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYTK
DataOraFonteTitoloSimboloCompagnia
03/01/202522:00GlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:CYTKCytokinetics Inc
23/12/202413:30GlobeNewswire Inc.Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
20/12/202406:00GlobeNewswire Inc.Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater ChinaNASDAQ:CYTKCytokinetics Inc
17/12/202401:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
16/12/202422:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTKCytokinetics Inc
16/12/202422:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
03/12/202422:00GlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CYTKCytokinetics Inc
03/12/202413:30GlobeNewswire Inc.Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection FractionNASDAQ:CYTKCytokinetics Inc
02/12/202422:00GlobeNewswire Inc.Cytokinetics to Participate in December Investor ConferencesNASDAQ:CYTKCytokinetics Inc
02/12/202413:30GlobeNewswire Inc.Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
19/11/202408:30GlobeNewswire Inc.Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in JapanNASDAQ:CYTKCytokinetics Inc
16/11/202415:00GlobeNewswire Inc.Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024NASDAQ:CYTKCytokinetics Inc
16/11/202415:00GlobeNewswire Inc.Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024NASDAQ:CYTKCytokinetics Inc
14/11/202419:28Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CYTKCytokinetics Inc
12/11/202422:00GlobeNewswire Inc.Cytokinetics to Participate in the 2024 Jefferies London Healthcare ConferenceNASDAQ:CYTKCytokinetics Inc
12/11/202417:44Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CYTKCytokinetics Inc
11/11/202413:30GlobeNewswire Inc.Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089NASDAQ:CYTKCytokinetics Inc
07/11/202422:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYTKCytokinetics Inc
06/11/202422:00GlobeNewswire Inc.Cytokinetics Reports Third Quarter 2024 Financial ResultsNASDAQ:CYTKCytokinetics Inc
05/11/202422:00GlobeNewswire Inc.Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024NASDAQ:CYTKCytokinetics Inc
23/10/202422:00GlobeNewswire Inc.Cytokinetics to Announce Third Quarter Results on November 6, 2024NASDAQ:CYTKCytokinetics Inc
16/10/202413:30GlobeNewswire Inc.Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst DayNASDAQ:CYTKCytokinetics Inc
02/10/202422:00GlobeNewswire Inc.Cytokinetics to Host Investor & Analyst Day on October 16, 2024NASDAQ:CYTKCytokinetics Inc
30/09/202415:20GlobeNewswire Inc.Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific MeetingNASDAQ:CYTKCytokinetics Inc
27/09/202417:00GlobeNewswire Inc.Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific SessionsNASDAQ:CYTKCytokinetics Inc
24/09/202413:30GlobeNewswire Inc.Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant ProgramNASDAQ:CYTKCytokinetics Inc
19/09/202422:00GlobeNewswire Inc.Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific MeetingNASDAQ:CYTKCytokinetics Inc
09/09/202413:30GlobeNewswire Inc.Cytokinetics Announces Data From Phase 1 Study of CK-4021586NASDAQ:CYTKCytokinetics Inc
05/09/202422:00GlobeNewswire Inc.Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual MeetingNASDAQ:CYTKCytokinetics Inc
01/09/202410:27GlobeNewswire Inc.Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024NASDAQ:CYTKCytokinetics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYTK

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
SPM
Saipem
BIT
CPR
Davide Campari
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
TIT
Telecom Italia
BIT
IVG
Iveco Group NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TEN
Tenaris
BIT
MONC
Moncler
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network